REN and chronic kidney disease: Renoprotection from renin-angiotensin-aldosterone (RAAS) blockade in diabetic and non-diabetic chronic kidney disease (CKD) is a well-established and generally accepted cardinal cornerstone of modern medical practice, and this consensus is based on a preponderance of large multicenter randomized clinical trials [1-5].